Format
Sort by
Items per page

Send to

Choose Destination

Best matches for GLATIRAMER/TU:

Search results

Items: 1 to 20 of 173

1.

[Effect of preventive treatment on cognitive performance in patients with multiple sclerosis].

Shorobura MS.

Wiad Lek. 2018;71(3 pt 2):648-652. Ukrainian.

PMID:
29783240
2.

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.

Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, Kuwabara S.

J Neurol. 2018 May;265(5):1145-1150. doi: 10.1007/s00415-018-8813-z. Epub 2018 Mar 12.

PMID:
29532286
3.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
4.

Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.

Omura S, Sato F, Martinez NE, Range T, Ekshyyan L, Minagar A, Alexander JS, Tsunoda I.

Arch Virol. 2018 May;163(5):1279-1284. doi: 10.1007/s00705-018-3729-6. Epub 2018 Jan 23.

PMID:
29362931
5.

Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.

Armoiry X, Kan A, Melendez-Torres GJ, Court R, Sutcliffe P, Auguste P, Madan J, Counsell C, Clarke A.

J Neurol. 2018 May;265(5):999-1009. doi: 10.1007/s00415-018-8752-8. Epub 2018 Jan 22. Review.

6.

Effects of multiple sclerosis and medications on menopausal age.

Türk Börü Ü, Köseoğlu Toksoy C, Bölük C, Bilgiç A, Taşdemir M.

J Int Med Res. 2018 Mar;46(3):1249-1253. doi: 10.1177/0300060517746026. Epub 2018 Jan 14.

7.

Multiple Sclerosis.

Reich DS, Lucchinetti CF, Calabresi PA.

N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. Review. No abstract available.

PMID:
29320652
8.

Multiple sclerosis, a treatable disease .

Doshi A, Chataway J.

Clin Med (Lond). 2017 Dec;17(6):530-536. doi: 10.7861/clinmedicine.17-6-530. Review.

PMID:
29196354
9.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

PMID:
29141831
10.

The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Tatomir A, Talpos-Caia A, Anselmo F, Kruszewski AM, Boodhoo D, Rus V, Rus H.

Immunol Res. 2017 Dec;65(6):1103-1109. doi: 10.1007/s12026-017-8961-8. Review.

PMID:
29116612
11.

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.

Kulakova O, Bashinskaya V, Kiselev I, Baulina N, Tsareva E, Nikolaev R, Kozin M, Shchur S, Favorov A, Boyko A, Favorova O.

Pharmacogenomics. 2017 Nov;18(17):1563-1574. doi: 10.2217/pgs-2017-0058. Epub 2017 Nov 2.

PMID:
29095108
12.

Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis.

de J Guerrero-García J, Rojas-Mayorquín AE, Valle Y, Padilla-Gutiérrez JR, Castañeda-Moreno VA, Mireles-Ramírez MA, Muñoz-Valle JF, Ortuño-Sahagún D.

Immunobiology. 2018 Jan;223(1):135-141. doi: 10.1016/j.imbio.2017.10.001. Epub 2017 Oct 5.

PMID:
29050818
13.

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.

Melendez-Torres GJ, Auguste P, Armoiry X, Maheswaran H, Court R, Madan J, Kan A, Lin S, Counsell C, Patterson J, Rodrigues J, Ciccarelli O, Fraser H, Clarke A.

Health Technol Assess. 2017 Sep;21(52):1-352. doi: 10.3310/hta21520. Review.

14.

Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.

Williams MJ, Johnson K, Trenz HM, Korrer S, Halpern R, Park Y, Herrera V.

Curr Med Res Opin. 2018 Jan;34(1):107-115. doi: 10.1080/03007995.2017.1374937. Epub 2017 Oct 3.

PMID:
28857632
15.

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.

Brænne I, Zeng L, Willenborg C, Tragante V, Kessler T; CARDIoGRAM Consortium; CARDIoGRAMplusC4D Consortium, Willer CJ, Laakso M, Wallentin L, Franks PW, Salomaa V, Dehghan A, Meitinger T, Samani NJ, Asselbergs FW, Erdmann J, Schunkert H.

PLoS One. 2017 Aug 22;12(8):e0182999. doi: 10.1371/journal.pone.0182999. eCollection 2017.

16.

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.

Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.

Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25.

17.

Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.

Ozakbas S, Cinar BP, Kosehasanoğullari G, Kahraman T, Oz D, Kursun BB.

Clin Neurol Neurosurg. 2017 Sep;160:69-72. doi: 10.1016/j.clineuro.2017.06.016. Epub 2017 Jun 27.

PMID:
28689102
18.

Continuous In-Home Symptom and Mobility Measures for Individuals With Multiple Sclerosis: A Case Presentation.

Newland P, Kimutis A, Salter A, Flick L, Thomas FP, Rantz M, Skubic M.

J Neurosci Nurs. 2017 Aug;49(4):241-246. doi: 10.1097/JNN.0000000000000299.

PMID:
28661948
19.

Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.

Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A.

Clin Immunol. 2017 Aug;181:83-88. doi: 10.1016/j.clim.2017.06.006. Epub 2017 Jun 19.

PMID:
28642148
20.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

Supplemental Content

Loading ...
Support Center